10% OFF DISCOUNT FOR VETERANS & FIRST RESPONDERS 
We are committed to making a positive impact on mental health awareness! Five percent [5%] of all profits will be directly donated to mental health related causes.
Mental health conditions can affect how a person thinks, feels, sleeps, works, and connects with others. According to The National Institute of Mental Health, more than one in five U.S. adults lives with a mental illness, representing an estimated 59.3 million people based on 2022 data.
Therapy and conventional medications help many people, but some continue to experience serious symptoms despite trying several treatment approaches. For individuals living with treatment-resistant depression, anxiety, post-traumatic stress disorder, or related conditions, ketamine therapy may offer another option to discuss with a qualified medical provider.
At K Plus Clinics in Orlando, Florida, ketamine IV infusions are administered in a medically supervised environment for eligible patients throughout Orlando and Central Florida.
Ketamine is a medication that has been used in medicine for decades. The FDA has approved it for the induction and maintenance of general anesthesia. Its use for depression and other psychiatric conditions is considered off-label, meaning the medication is being prescribed for a condition that is not included in its FDA-approved labeling.
Off-label prescribing is a common medical practice, but it does not mean ketamine is appropriate for everyone. Patients should complete a thorough medical and psychiatric evaluation before beginning treatment.
Ketamine is also different from esketamine, a related nasal-spray medication sold under the brand name Spravato. Esketamine has separate FDA approvals and treatment requirements. IV ketamine and intranasal esketamine should not be treated as interchangeable therapies.
Many conventional antidepressants primarily affect neurotransmitters such as serotonin, norepinephrine, or dopamine. They often need to be taken every day and may require several weeks before patients notice meaningful improvement.
Ketamine works through a different pathway involving glutamate, the brain’s most abundant excitatory neurotransmitter. Glutamate plays a major role in learning, memory, emotional regulation, and communication between brain cells. Research into ketamine’s antidepressant effects has focused heavily on its interaction with NMDA and AMPA receptors within this system.
Ketamine is classified as an NMDA receptor antagonist. Its effects are complex, but researchers believe that temporarily blocking certain NMDA receptors may trigger a surge in glutamate signaling through AMPA receptors.
This process appears to activate several downstream pathways associated with healthier communication between neurons.
One of the most important concepts in understanding ketamine therapy is neuroplasticity. This is the brain’s ability to adapt, reorganize, and form new connections.
Chronic stress and depression have been associated with disrupted communication between brain cells and changes in regions involved in mood, motivation, memory, and emotional regulation. Ketamine may temporarily increase synaptic plasticity, helping brain cells form or strengthen connections more efficiently. Current scientific reviews describe synaptic plasticity as a central part of ketamine’s rapid antidepressant action.
Ketamine has also been associated with pathways involving brain-derived neurotrophic factor, commonly called BDNF. This protein supports the growth, survival, and adaptability of neurons. However, ketamine’s exact antidepressant mechanism is still being studied, and researchers do not believe that one receptor or pathway explains every effect.
A useful way to think about ketamine is that it may create a temporary period in which the brain becomes more receptive to change. It does not erase difficult experiences or automatically replace unhealthy thought patterns. Instead, it may provide an opportunity for patients to make greater progress through psychotherapy, lifestyle changes, and other components of a comprehensive treatment plan.
Ketamine has received significant attention because some patients report improvement much sooner than they would with a conventional antidepressant.
A controlled study involving people with treatment-resistant depression found that 64% of participants receiving ketamine met response criteria after 24 hours, compared with 28% of those receiving midazolam, an active placebo.
A larger randomized trial later compared IV ketamine with electroconvulsive therapy in 365 patients with treatment-resistant major depression without psychosis. During the three-week initial treatment phase, patients received ketamine twice weekly or ECT three times weekly. Ketamine was found to be noninferior to ECT for the study’s primary response outcome.
These findings do not mean every patient will respond, and improvements may not last indefinitely. Initial treatment often involves a short series of infusions, followed by individualized maintenance or booster treatments when clinically appropriate.
The strongest evidence currently supports ketamine’s use in certain patients with treatment-resistant depression. Research is also evaluating its potential role in conditions such as:
Evidence varies considerably by condition. Reviews have found relatively strong support for rapid but sometimes temporary antidepressant effects, while research for many other psychiatric uses remains preliminary.
Ketamine should therefore be presented as a potential treatment option—not a guaranteed cure for every mental health condition.
At K Plus Clinics, patients begin with an evaluation of their health history, current medications, symptoms, previous treatments, and personal goals.
During an IV infusion, a carefully calculated dose of ketamine is administered gradually while the clinical team monitors the patient’s blood pressure, heart rate, oxygen level, and overall comfort.
Temporary effects may include:
Patients must arrange transportation home and should not drive, work, drink alcohol, or make major decisions for the remainder of the treatment day.
Ketamine therapy is not a replacement for all medications, psychotherapy, or ongoing psychiatric care. For the right candidate, however, it may provide a different way of addressing symptoms that have not improved through conventional treatments.
Located in Orlando, Florida, K Plus Clinics serves patients from Orlando and surrounding Central Florida communities. Our team provides personalized, medically supervised IV ketamine therapy in a calm and supportive clinical environment.
Contact K Plus Clinics to schedule a consultation and learn whether ketamine therapy may be appropriate for your mental health treatment plan.
